Doxazosin: Independent Evidence on Blood Pressure, BPH & Risks

Table of contents

• Evidence summary
• What doxazosin is
• How it works
• What it is prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid doxazosin
• Dosage and how to take it
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or professional-society team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D. Sources cluster in the UK and US, with Pfizer-funded work from the UK, Switzerland, Germany, France and the US.

What doxazosin is

Doxazosin is a quinazoline alpha-1 adrenergic blocker. The US label lists contraindication for people allergic to it or to other quinazolines such as prazosin and terazosin (US label).

• Brand name: Cardura. The tablets come in 1 mg, 2 mg, 4 mg and 8 mg strengths in the US (US label). A modified-release form (doxazosin GITS or "XL") was used in ASCOT and PATHWAY-2 (PATHWAY-2).
• Licence holders: The US label we reviewed names Roerig, a division of Pfizer. The current UK SmPC names Viatris Products Limited, marketing authorisation PL 46302/0270 (UK SmPC).
• Prescription status: Prescription-only in the UK ("Prescription only" on the SmPC) and the US. The NHS says it is usually taken as a tablet once a day (NHS).
• Half-life: About 22 hours, with peak levels at 2 to 3 hours and about 65% bioavailability (US label). Prazosin has a half-life of about 2 to 3 hours (Richardson 2025), which is why prazosin is taken more than once a day.

How it works

Doxazosin blocks alpha-1 receptors, which sit on smooth muscle in blood vessels and in the prostate and bladder neck. In blood vessels, blocking them relaxes the vessel wall and lowers pressure. In the prostate, relaxing the muscle is meant to ease urine flow. The Cardura label classes it as an alpha-1 adrenergic antagonist (US label).

The same action explains the main side effects. When a person stands, the body normally tightens blood vessels to hold pressure up. An alpha-1 blocker dampens that reflex, so dizziness and fainting on standing are expected effects, not rare surprises (US label).

What is proven in humans: lowering blood pressure and improving BPH symptom scores (see below). What is proposed but weaker: effects on nightmares, cocaine use and other conditions, which come from small trials and case reports (Richardson 2025).

Pharmacokinetics that matter in practice

• Liver: Doxazosin is extensively metabolised in the liver. Exposure rises in liver disease, and the US label says use is "not recommended" in severe impairment (Child-Pugh class C) (US label).
• CYP3A4: It is a substrate of this enzyme, so strong inhibitors can raise levels (US label).
• Kidney: The UK SmPC says the usual adult dose applies in renal impairment (UK SmPC).

What it is prescribed for

Licensed uses

Where guidelines place it

• Resistant hypertension, Europe: A 2025 review sets out that the 2023 ESH guideline lets prescribers choose a beta-blocker, alpha-blocker or centrally acting drug as a fourth drug when kidney function is adequate (eGFR 30 or above), with spironolactone or similar drugs preferred. It reports the 2024 ESC guideline names spironolactone as the preferred addition (Schmieder 2025). We read this second-hand because we could not open the guidelines themselves.
• UK: A research-funder summary says NICE recommends spironolactone at 25 mg, half the top dose used in PATHWAY-2 (NIHR Evidence). The NICE guideline page blocked automated access, so we did not confirm what it says about alpha-blockers.
• Older adults: The 2023 Beers Criteria say to avoid peripheral alpha-1 blockers (doxazosin, prazosin, terazosin) as hypertension treatment because of a "high risk of orthostatic hypotension" (AGS Beers 2023).
• BPH: An American Urological Association guideline on medical management of lower urinary tract symptoms was published in 2026 (AUA 2026, Part II). It is paywalled, so we read only its abstract and cannot report its alpha-blocker recommendations.

What works and what does not

Benefits by claim

Does doxazosin protect the heart? ALLHAT

ALLHAT randomised older adults with high blood pressure to chlorthalidone, doxazosin, amlodipine or lisinopril. The doxazosin arm was stopped in January 2000 after an interim analysis. At that point 9,067 people were on doxazosin and 15,268 on chlorthalidone (Medsafe 2001; ALLHAT 2000).

• Heart attack and coronary death: 365 vs 608 events, RR 1.03 (95% CI 0.90 to 1.17). No difference.
• All-cause death at 4 years: 9.62% vs 9.08%, RR 1.03 (0.90 to 1.15). No difference.
• Stroke: RR 1.19 (1.01 to 1.40), higher on doxazosin.
• Combined cardiovascular disease at 4 years: 25.45% vs 21.76%, RR 1.25 (1.17 to 1.33).
• Heart failure at 4 years: 8.13% vs 4.45%, RR 2.04 (1.79 to 2.32).

In plain terms, doxazosin did not save more lives or prevent more heart attacks, and it was linked to roughly twice as many cases of heart failure. The ACC summary adds that people with symptomatic heart failure at the start were excluded (ACC ALLHAT summary). So the extra heart failure arose in people who did not have it at the start. The New Zealand regulator also noted that doxazosin lowered systolic pressure about 3 mmHg less than chlorthalidone (Medsafe 2001).

The signal held in a sub-analysis of people with diabetes. Heart failure RR was 1.85 (1.56 to 2.19) in 8,749 people with known diabetes (Barzilay 2004).

Limits. The comparator was a diuretic, a drug class with strong heart-failure prevention evidence, so the trial shows doxazosin is worse than chlorthalidone, not that it harms heart function. Medsafe's bulletin said the picture for BPH was less clear because doxazosin helps symptoms (Medsafe 2001).

Doxazosin as an add-on: ASCOT-BPLA

ASCOT-BPLA randomised 19,257 people to amlodipine (adding perindopril as needed) or atenolol (adding bendroflumethiazide as needed). The main result: coronary events HR 0.90 (95% CI 0.79 to 1.02), stroke HR 0.77 (0.66 to 0.89) and all-cause death HR 0.89 (0.81 to 0.99), all in favour of the amlodipine-based regimen (Dahlöf 2005). Doxazosin GITS was the common third drug in both arms, at the physician's discretion.

In 10,069 people who needed it, blood pressure fell 11.7/6.9 mmHg over a median of 12 months of continuous treatment. 29.7% reached target. The authors saw "no excess heart failure". Doxazosin was added to a mean of 2.0 other drugs, and the mean final dose was 7.0 mg (Chapman 2008). This is a real-world observation, not a comparison. There was no placebo group, no randomisation to doxazosin, and the funder of ASCOT also made doxazosin (Gupta 2024 funding statement). The result is consistent with doxazosin lowering pressure as a late add-on. It cannot overturn ALLHAT.

Resistant hypertension: PATHWAY-2

PATHWAY-2 enrolled 335 adults with uncontrolled blood pressure despite three drugs (an ACE inhibitor or ARB, a calcium channel blocker and a diuretic). Each took spironolactone (25 to 50 mg), bisoprolol (5 to 10 mg), modified-release doxazosin (4 to 8 mg) and placebo, for 12 weeks each in random order. Spironolactone lowered home systolic pressure by 8.70 mmHg more than placebo (95% CI 7.69 to 9.72), and by 4.03 mmHg more than doxazosin (3.02 to 5.04) (Williams 2015).

A summary of the trial reports doxazosin cut home systolic pressure by 9.1 mmHg from baseline vs 4.2 on placebo, and that 42% reached a home goal below 135 mmHg, vs 58% on spironolactone and 24% on placebo. It also notes that stopping because of side effects was about three times as common on doxazosin as on spironolactone (PURLs). In plain terms, doxazosin is a real but second-best choice for the fourth drug.

Benign prostatic hyperplasia

BPH is a non-cancerous enlargement of the prostate. The Cardura label advises ruling out prostate cancer before starting it for BPH (US label).

• Independent view: In a network meta-analysis of 22 trials and 3,371 patients, tamsulosin 0.4 mg had the highest ranking for symptom score, urine flow and residual volume. Doxazosin 8 mg had the highest ranking for quality of life. Doxazosin had 27 adverse events among 313 participants. The authors said larger, long-term studies are needed (Yoosuf 2024).
• Sponsor view: A Pfizer-sponsored network meta-analysis of 40 publications (12,201 men) found doxazosin GITS 4 mg gave the largest IPSS improvement (-10.07) and was superior to most tamsulosin doses on total, storage and quality-of-life scores. It found no differences between doses for the voiding subscore, urine flow or residual volume. It did not assess individual side effects such as dizziness (Oelke 2026).

The two analyses reach different rankings. We read that as evidence that alpha-blockers are broadly similar for BPH, with the choice usually decided by side effects, such as ejaculation problems or dizziness, and by price. Neither analysis is a head-to-head, long-term, blinded trial.

PTSD nightmares and addiction

Doxazosin has been tried off-label because it blocks the same receptors as prazosin but lasts longer. A 2025 scoping review found 23 relevant articles, mostly small open-label trials and case reports, with "surprisingly a lack of" randomised trials for PTSD. One randomised PTSD trial had 8 male veterans. A 92-veteran trial in PTSD with alcohol use disorder showed no significant PTSD-score difference from placebo (Richardson 2025). Dizziness, fatigue and one fainting episode were among the reported effects. See our review of prazosin for PTSD nightmares for the better-studied drug.

Risks and all side effects

Common side effects (label trials)

The figures are from the US label (US label). The NHS lists headaches, dizziness, vertigo, ankle swelling, flu-like symptoms, tummy pain, nausea and vomiting as common (NHS). In ASCOT, 7.5% of people given doxazosin as a third drug stopped for adverse events, most often dizziness, fatigue, headache and oedema (Chapman 2008).

Serious and rare risks

Falls and older adults

The Beers Criteria warn about orthostatic hypotension and harm in older adults when peripheral alpha-1 blockers are used for hypertension (AGS Beers 2023). Dizziness was the top reported side effect in the label trials, so falls are a practical concern.

Overdose

We did not find overdose figures in the label text we reviewed. Take any suspected overdose seriously. The NHS advises calling NHS 111 if you take too much (NHS).

All interactions

We did not review a full interaction database. Ask a pharmacist to check any new prescription, over-the-counter or herbal medicine against doxazosin.

Who should avoid doxazosin

Contraindications

• US: hypersensitivity to doxazosin, other quinazolines (prazosin, terazosin) or any ingredient (US label).
• UK: hypersensitivity to quinazolines; a history of orthostatic hypotension; for the BPH indication, upper urinary tract congestion, chronic urinary tract infection or bladder stones, and low blood pressure; use alone in overflow bladder or anuria (UK SmPC).

Use with care

The tablets contain lactose (UK SmPC). The NHS says it may not suit people with an enlarged prostate and low blood pressure, or with bladder or kidney problems (NHS).

Children

The UK SmPC says paediatric use is not established. The NHS says a specialist may give it to children for high blood pressure or bladder problems (UK SmPC; NHS).

Older adults

The UK SmPC gives the normal adult dose for older people. The Beers Criteria advise avoiding it for hypertension in older adults (UK SmPC; AGS Beers 2023). The two documents do not conflict: one gives the label dose, the other judges the risk.

Pregnancy and breastfeeding

• Pregnancy: Human data are limited. The US label notes animal studies without adverse developmental effects and untreated hypertension also carries risks. The UK SmPC says to use it only if benefit outweighs risk (US label; UK SmPC). The NHS says it is not usually used in pregnancy unless benefits outweigh risks.
• Breastfeeding: Limited data. One case report found the drug in milk at under 1% of the weight-adjusted maternal dose (US label).

Liver disease

Not recommended in severe impairment. Monitor blood pressure in mild to moderate impairment (US label; UK SmPC).

Before eye or prostate procedures

Tell the eye surgeon before cataract surgery (UK SmPC). Prostate cancer should be ruled out before treating BPH (US label).

Dosage and how to take it

Your prescriber sets the dose. The ranges below are official label doses and trial doses, given for context only. They are not a guide to self-dosing.

How to take it

The NHS says it is usually a tablet swallowed with water once a day at the same time. If a dose is missed, take it when remembered unless the next dose is nearly due, and never take two doses to make up. Treatment is often long term, possibly several years. If dizzy, do not drive, cycle or use machinery until the symptoms stop (NHS). The UK SmPC says the ability to drive or use machinery may be impaired, especially when starting treatment (UK SmPC).

How long before it works

We did not find a label statement on time to full effect for BPH. PATHWAY-2 measured pressure after 12 weeks on each drug, with the dose doubled after 6 weeks (PATHWAY-2).

How to stop

The only stopping advice we found on the label is to restart at the initial regimen after several days off (US label). Stopping should be planned with your prescriber, because blood pressure and urinary symptoms can change.

Follow the money: who makes it and who funded the evidence

Who made it, and who sells it now

• Originator brand: Cardura, a Pfizer brand. The US label we reviewed is by Roerig, a division of Pfizer (US label). We did not find a document giving the original approval date.
• Current UK licence holder: Viatris Products Limited, Potters Bar (UK SmPC). Viatris was formed when Pfizer's off-patent branded business, Upjohn, merged with Mylan; the trade press reported it formed in November 2020. It is headquartered in the US (Pharmacy Magazine).
• Generics: The Cardura label discusses "doxazosin" generically and Public Citizen's 2001 testimony refers to "Cardura and its generics" (Public Citizen 2001). We did not catalogue current generic makers or market size.

Documented events

On 24 May 2001, two staff of the consumer group Public Citizen testified to the FDA's Cardiovascular and Renal Drugs Advisory Committee in support of a citizen petition. The petition asked the FDA to require Pfizer to notify US patients taking Cardura of the interim ALLHAT results, to require a boxed warning, and to consider further labelling changes. Public Citizen wanted more: a patient Medication Guide, a class boxed warning for all alpha-blockers and labelling placing them as second-line or lower for hypertension (Public Citizen 2001). Public Citizen is an advocacy group, and the page did not state its funders. We could not open trade-press items that describe the committee's vote, a 2000 product-liability class action, or Cardura XL manufacturing recalls, so we do not rely on them. The label today carries warnings on syncope, floppy iris and priapism but we saw no boxed warning on the version we reviewed.

Who funded the evidence

• ALLHAT: Sponsored by the US NHLBI, part of the National Institutes of Health. Study visits ended in 2000 and the trial began in 1994 (NHLBI). The diabetes sub-analysis lists NHLBI contract N01-HC-35130 and states that ALLHAT investigators received study medications from Pfizer (amlodipine and doxazosin), AstraZeneca and Bristol-Myers Squibb, and financial support from Pfizer (Barzilay 2004). So the doxazosin arm was tested with the maker's own tablets, and the maker's support did not stop the result.
• ASCOT: "The original ASCOT study and the ASCOT-10 study were funded by Pfizer", according to a later ASCOT paper. Two senior ASCOT authors declared consulting or research support from Pfizer, and one also from Viatris (Gupta 2024). Doxazosin GITS was the common third drug (Chapman 2008).
• PATHWAY-2: British Heart Foundation, Medical Research Council and NIHR grants (Europe PMC grant list). The UK funder's summary names a British Heart Foundation special project grant and NIHR support (NIHR Evidence). The NIHR site is produced for the NIHR and carries the Department of Health and Social Care funding logo.
• BPH comparisons: The "doxazosin is best" analysis was "sponsored by Pfizer" with Viatris employee and staff input (Oelke 2026). The analysis that ranked tamsulosin first came from Indian academics with no competing interests (Yoosuf 2024).

What this means: The strongest warning about doxazosin comes from a government-run trial that Pfizer helped supply and support, and whose result went against Pfizer's own product. The most favourable evidence, the add-on data and the "best for BPH" ranking, is sponsor-funded or sponsor-linked. Where the sponsor-linked and independent analyses disagree on BPH, we have shown both. They agree that doxazosin relieves symptoms.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Hypertension: accurate measurement, treatment, safety and evidence funding
• Resistant hypertension: confirming the diagnosis, treatment and funding
• Blood pressure medicines: types, monitoring, side effects and safety
• Home blood pressure monitoring
• Orthostatic hypotension: blood-pressure drops on standing and care
• Prazosin for PTSD nightmares: independent evidence and safety
• Amlodipine: blood pressure and angina uses, swelling and safety
• Heart failure: treatment evidence, supplement limits and safety
• Sex and heart disease: recovery, intimacy, erectile dysfunction and nitrate safety
• Vasovagal syncope: reflex fainting
• Nocturia and sleep-related urinary dysfunction
• Prostate cancer: PSA, biopsy, active surveillance and treatment risks

Frequently asked questions

Sources and funding notes

What we could not verify: We could not open the NICE guideline NG136 (access blocked), the ESH 2023 and ESC 2024 guidelines themselves (read second-hand through a 2025 review), or the AUA 2026 BPH guideline text (paywalled). The PATHWAY-2 record we saw had no competing-interests statement. The funding of the Chapman 2008, Yoosuf 2024 and Wang 2022 papers was not visible in the parts we read. We could not open trade-press reports of a 2000 lawsuit, the 2001 FDA committee vote, and recalls of Cardura XL, so we leave them out. We did not catalogue current generic makers, sales figures or the original approval date. We did not find a doxazosin-specific regulator enforcement action, but our search was not exhaustive. All sources were found through web search and opened via web fetch only.

1. Cardura (doxazosin mesylate) US prescribing information, Roerig/Pfizer, revised 6/2021 — role: label text, doses, warnings, interactions; funder: manufacturer, FDA-approved.
2. Cardura 2 mg Tablets SmPC, Viatris Products Limited (text revised 01/2026) — role: UK licence, contraindications, interactions; funder: licence holder, regulator-approved.
3. NHS: Doxazosin (reviewed 3 August 2026) — role: patient information; funder: UK state.
4. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000 — role: key trial; funder: NHLBI; Pfizer supplied doxazosin and financial support to investigators (per Barzilay 2004).
5. Barzilay JI et al. Cardiovascular outcomes using doxazosin vs chlorthalidone in older adults with and without glucose disorders (ALLHAT). J Clin Hypertens 2004 — role: sub-analysis; funder: NHLBI contract N01-HC-35130; Pfizer supplied study drugs and investigator support.
6. NHLBI: ALLHAT — role: trial sponsor description; funder: US government.
7. American College of Cardiology: ALLHAT summary — role: trial design and exclusions; funder: professional society; sponsor not stated on the page.
8. Medsafe (New Zealand), Prescriber Update, February 2001 — role: regulator reading of ALLHAT; funder: NZ government; the page warns it is more than five years old.
9. Dahlöf B et al. ASCOT-BPLA. Lancet 2005 — role: main trial; funder: Pfizer per later ASCOT paper.
10. Chapman N et al. Doxazosin GITS as third-line therapy in ASCOT. Circulation 2008 — role: add-on analysis; funder: not in record; ASCOT funded by Pfizer.
11. Gupta A et al. Long-term cardiovascular benefits of blood pressure treatment in ASCOT, mediated mainly by blood pressure variability (2024) — role: ASCOT funding statement; funder: Imperial College London for that study; Pfizer for the original ASCOT.
12. Williams B et al. PATHWAY-2. Lancet 2015 — role: resistant hypertension trial; funder: British Heart Foundation, MRC, NIHR.
13. Kaysin A, Mounsey A. PURLs: Resistant hypertension? J Fam Pract 2016 — role: summary of PATHWAY-2 numbers; funder: US NCRR Clinical Translational Science Award supports the PURLs service.
14. NIHR Evidence: Spironolactone is effective for treating resistant hypertension — role: plain summary and NICE dose mention; funder: UK Department of Health and Social Care via NIHR.
15. Schmieder RE. 2025 update on resistant hypertension in CKD. Clin Kidney J 2025 — role: ESH/ESC positions; funder: supplement supported by the European Renal Association; "None declared".
16. American Geriatrics Society 2023 Beers Criteria — role: avoid in older adults for hypertension; funder: no sponsor stated.
17. Wang YH et al. Risk of IFIS among selective alpha-1 blockers. Front Med 2022 — role: floppy iris meta-analysis; funder: not found; no conflicts.
18. Yoosuf BT et al. Alpha-blockers as monotherapy for BPH: network meta-analysis. Sci Rep 2024 — role: independent BPH comparison; funder: not found in the part we read.
19. Oelke M et al. Doxazosin versus tamsulosin for LUTS/BPH. World J Urol 2026 — role: sponsor-funded BPH comparison; funder: Pfizer.
20. Goueli R et al. AUA Guideline (2026) Part II: Medical Management of LUTS/BPH. J Urol 2026 — role: guideline existence; funder: AUA; abstract only.
21. Niaga KJK et al. Alpha-blockers, 5-ARIs and dementia risk: network meta-analysis. Int Neurourol J 2025 — role: noted, abstract only; funder: not stated.
22. Richardson CS et al. Doxazosin for mental health disorders: scoping review. PLOS Mental Health 2025 — role: PTSD and addiction evidence; funder: none.
23. Public Citizen: Testimony on petition to relabel doxazosin (Cardura), 24 May 2001 — role: documented petition; funder: not stated on the page; consumer advocacy group (tier 3, credibility B).
24. Pharmacy Magazine: Viatris formed with merger of Upjohn and Mylan (18 November 2020) — role: corporate background; funder: trade press.

Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.